Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Ariad Pharmaceuticals.

Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease Continuum

Release Date: August 29, 2017
Expiration Date: August 29, 2018
Media: Internet - based


Activity Overview

Treatment approaches for anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) have been shaped by the emergence of targeted therapies that have demonstrated improved clinical efficacy. However, many perplexing challenges in the treatment of ALK-positive NSCLC remain, including the frequent development of treatment resistance and how to best treat patients with these tumors who have brain metastases. Treatment-related toxicities and the need to establish optimal sequencing of therapy together present another layer of complexity in the management of these patients. Moreover, novel ALK-targeted strategies are advancing through clinical investigation and the approval process; this is great news for patients because these may provide more treatment options. To help clinicians with the management of these challenges, this educational activity has been developed, featuring insights from leading experts in NSCLC management. Multiple topics will be explored, including optimal management strategies for treatment-naïve patients, treatment approaches for patients who have relapsed, and tumor testing strategies.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Ariad Pharmaceuticals.

CME Activity Table of Contents

  • The Treatment-Naïve Patient With ALK-Positive NSCLC
    Commentary featuring Justin F. Gainor, MD, and David R. Gandara, MD
  • The Treatment-Naïve Patient With ALK-Positive NSCLC and CNS Metastases
    Commentary featuring D. Ross Camidge, MD, PhD
  • Sequencing Decisions for Patients With ALK-Positive NSCLC Beyond Disease Progression
    Commentary featuring H. Jack West, MD Evolution of Tumor Biology After Therapy: Biopsy/Rebiopsy/Plasma Cell-Free DNA Assessment
    Commentary featuring Christine M. Lovly, MD, PhD

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists interested in the treatment of lung cancer. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with lung cancer are also invited to participate. This CME-certified activity will also be made available to patients with lung cancer as an educational reference material.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Assess approaches to address the problem of acquired resistance and relapse in patients with ALK-positive, non‒small cell lung cancer (NSCLC)
  • Determine evolving methods to facilitate and apply testing strategies along the disease continuum in the management of ALK-positive NSCLC
  • Apply clinical trial evidence to inform sequencing of therapies in patients with ALK-positive NSCLC, and proactively address treatment-related toxicities
  • Discuss methods to plan for and manage brain metastases in the care of patients with ALK-positive NSCLC

Faculty, Staff, and Planners' Disclosures


D. Ross Camidge, MD, PhD
Professor with Tenure, Division of Medical Oncology
Joyce Zeff Chair in Lung Cancer Research
University of Colorado, Denver, School of Medicine
Denver, CO

Disclosure: Grant Research Support: Ariad, Takeda; Consultant: Roche, Pfizer.

Justin F. Gainor, MD
Instructor, Medicine, Harvard Medical School
Attending Physician, Thoracic Oncology
Massachusetts General Hospital
Boston, MA

Disclosure: Consultant: Bristol-Myers Squibb, Genentech, Loxo, Clovis, Theravance; Honoraria: Merck, Roche, Incyte, Novartis.

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosure: Grant Research Support: Genentech, Novartis, AstraZeneca; Consultant: Genentech, Novartis, AstraZeneca.

Christine M. Lovly, MD, PhD
Assistant Professor of Medicine, Division of Hematology-Oncology
Assistant Professor of Cancer Biology
Vanderbilt University School of Medicine
Vanderbilt Ingram Cancer Center
Nashville, TN

Disclosure: Grant Research Support: Novartis (Grant brokered through Vanderbilt; Dr. Lovly does not directly receive funds); Consultant: Novartis, Ariad, Pfizer.

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
Founder & President, GRACE
Seattle, WA

Disclosure: Consultant: Ariad, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech/Roche, Guardant Health, Merck, Novartis, TrovaGene. Speakers Bureau: Ariad, Genentech/Roche, Eli Lilly.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By